Behavioral Neuroscience – News and Features

News
deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
Findings may provide the foundation for a test to complement standard clinical diagnosis, potentially enabling earlier intervention and treatment.

News
Liver Damage in Hepatitis C Patients Could be Treated with Warfarin
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

News
Mechanism for Postpartum Depression Found in Mice
Researchers have pinpointed a mechanism in the brains of mice that could explain why some human mothers become depressed following childbirth.

News
Alzheimer's Disease Patients Show Improvement in Trial of new Drug
A new drug has been shown to improve the brain function of Alzheimer's patients and reduce a key protein associated with the disease in the spinal fluid.

News
Scientists Predict new Uses for Existing Drugs from Their Side Effects
Researchers developed a computational method that compares how similar the side effects of different drugs are and predicts how likely the drugs act on the same target molecule.

News
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Phase 2 study shows that Dimebon™ significantly improved cognitive function in patients with mild-to-moderate Huntington’s disease.

News
Evotec’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.

News
The Wellcome Trust Case Control Consortium Selects Illumina DNA Analysis Products
Illumina's Infinium HD Human1M-Duo BeadChip to be used to analyze 90,000 DNA samples collected from study participants.

News
Lack of Fragile X, Related Gene Disrupts Sleep
Deficiency of the FMR1 gene and a similar gene called FXR2 could account for sleep problems associated with inherited mental impairment.

News
Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s Disease
The Company has commenced clinical trials of a potent, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6.
Advertisement